
AARD Stock Forecast & Price Target
AARD Analyst Ratings
Bulls say
Aardvark Therapeutics is a promising biopharmaceutical company with a strong focus on developing novel treatments for metabolic diseases, particularly targeting the Bitter Taste Receptors for hunger-associated conditions. Their lead product candidate, ARD-101, has already advanced to Phase 3 clinical trials for hyperphagia associated with PWS, showing potential for significant growth in the PWS market. While there are some potential risks to consider, such as efficacy and safety concerns, overall, Aardvark Therapeutics has a solid foundation and growth potential in the biopharmaceutical market.
Bears say
Aardvark Therapeutics is facing significant challenges and risks, with the FDA placing a full clinical hold on their lead compound, ARD-101, due to concerns about cardiac observations. This hold has resulted in the suspension of the Phase 3 HERO trial and requires a new trial to be conducted, putting the company's regulatory approval and potential partnership opportunities in jeopardy. Additionally, the company's cash runway may be limited, as it faces the need for additional clinical development and potential dilution risk. Overall, Aardvark therapeutics is in a precarious position, causing a negative outlook on its stock.
This aggregate rating is based on analysts' research of Aardvark Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
AARD Analyst Forecast & Price Prediction
Start investing in AARD
Order type
Buy in
Order amount
Est. shares
0 shares